MCID: ASH001
MIFTS: 36

Asherman's Syndrome

Categories: Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Asherman's Syndrome

MalaCards integrated aliases for Asherman's Syndrome:

Name: Asherman's Syndrome 19 75
Asherman Syndrome 19 58 71
Intrauterine Adhesions 71
Intrauterine Synechiae 19
Adhesions of Uterus 71
Uterine Synechiae 19

Characteristics:


Prevelance:

Asherman Syndrome: 1-5/10000 (Europe) 58

Age Of Onset:

Asherman Syndrome: Adult 58

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

ICD10 via Orphanet 32 N85.6
UMLS via Orphanet 72 C0156372 C0241593 C1704274
Orphanet 58 ORPHA137686
UMLS 71 C0156372 C0241593 C1704274

Summaries for Asherman's Syndrome

GARD: 19 A rare, acquired uterine disease characterized by intrauterine adhesions associated with a history of curettage or intrauterine surgery and gynecological symptoms (secondary amenorrhea, hypomenorrhea, pelvic pain, infertility or pregnancy loss).

MalaCards based summary: Asherman's Syndrome, also known as asherman syndrome, is related to adhesions of uterus and amenorrhea. The drugs Dydrogesterone and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include uterus, cervix and bone marrow, and related phenotypes are oligomenorrhea and decreased fertility in females

Orphanet: 58 A rare, acquired uterine disease characterized by intrauterine adhesions associated with a history of curettage or intrauterine surgery and gynecological symptoms (secondary amenorrhea, hypomenorrhea, pelvic pain, infertility or pregnancy loss).

Wikipedia: 75 Asherman's syndrome (AS) is an acquired uterine condition that occurs when scar tissue (adhesions) form... more...

Related Diseases for Asherman's Syndrome

Diseases related to Asherman's Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 adhesions of uterus 10.8
2 amenorrhea 10.6
3 infertility 10.6
4 placenta accreta 10.5
5 pregnancy loss, recurrent 1 10.3
6 myoma 10.2
7 rapidly involuting congenital hemangioma 10.2
8 endometritis 10.2
9 endometriosis 10.2
10 cervical incompetence 10.2
11 endometrial cancer 10.1
12 preterm premature rupture of the membranes 10.1
13 hypogonadotropic hypogonadism 10.1
14 hydatidiform mole, recurrent, 1 10.1
15 ectopic pregnancy 10.1
16 pre-eclampsia 10.1
17 gestational trophoblastic neoplasm 10.1
18 adenomyosis 10.1
19 gestational diabetes 10.1
20 premature menopause 10.0
21 endometrial adenocarcinoma 10.0
22 hypogonadotropic hypogonadism 7 with or without anosmia 10.0
23 scoliosis 10.0
24 thrombosis 10.0
25 hypogonadism 10.0
26 thrombophilia 10.0
27 bicornuate uterus 10.0
28 adult syndrome 10.0
29 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
30 mycobacterium tuberculosis 1 10.0
31 placenta praevia 10.0
32 schistosomiasis 10.0
33 hemometra 10.0
34 uterine inversion 10.0
35 cone-rod dystrophy 2 9.9
36 leiomyoma, uterine 9.9
37 uterine anomalies 9.9
38 intrahepatic cholestasis of pregnancy 9.9
39 oligohydramnios 9.9
40 cholestasis 9.9
41 intrahepatic cholestasis 9.9
42 gastric antral vascular ectasia 9.9
43 gastritis 9.9
44 severe combined immunodeficiency 9.9
45 placental abruption 9.9
46 septate uterus 9.9

Comorbidity relations with Asherman's Syndrome via Phenotypic Disease Network (PDN):


Adenomyosis Myofibroma

Graphical network of the top 20 diseases related to Asherman's Syndrome:



Diseases related to Asherman's Syndrome

Symptoms & Phenotypes for Asherman's Syndrome

Human phenotypes related to Asherman's Syndrome:

58 30 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 oligomenorrhea 58 30 Frequent (33%) Frequent (79-30%)
HP:0000876
2 decreased fertility in females 58 30 Frequent (33%) Frequent (79-30%)
HP:0000868
3 secondary amenorrhea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000869
4 infertility 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000789
5 dysmenorrhea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100607
6 metrorrhagia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100608
7 episodic abdominal pain 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002574
8 chronic infection 58 30 Very rare (1%) Very rare (<4-1%)
HP:0031035
9 abnormal placenta morphology 30 Very rare (1%) HP:0100767
10 abnormality of the menstrual cycle 58 Frequent (79-30%)
11 spontaneous abortion 58 Occasional (29-5%)
12 abnormality of the placenta 58 Very rare (<4-1%)

Drugs & Therapeutics for Asherman's Syndrome

Drugs for Asherman's Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
2
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
3
Dimenhydrinate Approved Phase 4 523-87-5 10660
4 Estrogens Phase 4
5 Hormone Antagonists Phase 4
6 Contraceptive Agents Phase 4
7 Progestins Phase 4
8 Adjuvants, Immunologic Phase 4
9 Viscosupplements Phase 4
10 Immunologic Factors Phase 4
11 Protective Agents Phase 4
12 Pharmaceutical Solutions Phase 4
13 Carboxymethylcellulose Sodium Phase 4
14
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
15
Polyestradiol phosphate Approved Phase 2 28014-46-2
16
Estrone Approved Phase 2 53-16-7 5870
17 Estradiol 3-benzoate Phase 2
18 Estradiol 17 beta-cypionate Phase 2
19
Estropipate Phase 2 7280-37-7
20 Anticoagulants Phase 2
21 Anti-Bacterial Agents Phase 1
22 Anesthetics Phase 1
23 Antibiotics, Antitubercular Phase 1
24
Carbamide peroxide Approved 124-43-6
25
Ethanol Approved Early Phase 1 64-17-5 702
26
Progesterone Approved, Vet_approved 57-83-0 5994
27
Heparin, bovine Approved, Investigational, Withdrawn 9005-49-6 22833565 9812414 772
28
Plerixafor Approved Early Phase 1 110078-46-1 65015
29 Fibrinolytic Agents
30 Calcium heparin
31 Hormones Early Phase 1
32 Antiviral Agents Early Phase 1
33 Anti-Retroviral Agents Early Phase 1
34 Anti-Infective Agents Early Phase 1
35 Anti-HIV Agents Early Phase 1
36 Chorionic Gonadotropin Early Phase 1
37
Ethylene 74-85-1 6325

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Clinical Study of the Treatment of Infertility Caused by Severe Intrauterine Adhesions by Collagen Scaffold Loaded With Autologous Bone Marrow Stem Cells Unknown status NCT02204358 Phase 4
2 Effectiveness of Self-cross-linked Hyaluronic Acid Gel in the Prevention of Intrauterine Adhesions After Second Trimester Abortion Unknown status NCT02868437 Phase 4
3 New Therapeutic Approaches to Treat Asherman's Syndrome and Endometrial Atrophy Based in BM Stem Cells Autologous Transplantation Completed NCT02144987 Phase 4
4 The Effect of Estrogen in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis Enrolling by invitation NCT03620929 Phase 4 Estradiol Valerate
5 Prevalence of Intrauterine Adhesions After the Application of Hyaluronic Acid Gel After Dilatation and Curettage in Women With Spontaneous Abortion or Induction of Abortion From 12+0 Till 23+6 Week of Pregnancy. Not yet recruiting NCT04671914 Phase 4 Hyaluronic Acid 20 MG/ML Injectable Solution
6 The Role of Seprafilm Bioresorbable Slurry in the Prevention of Intrauterine Synechiae in Patients Undergoing Hysteroscopic Myomectomy Terminated NCT01632202 Phase 4
7 Non-stick Gel Applicated After Scraping Surgery for Natural Miscarriage and Uterine Synechiae Prevention Completed NCT02248376 Phase 3 Gel
8 Platelet-Rich Plasma in the Management of Asherman Syndrome Completed NCT04308811 Phase 2
9 A Prospective, Randomized, Controlled Trial Comparing 2 Different Doses of Estrogen Therapy After Hysteroscopic Adhesiolysis as an Adjuvant to Prevent Recurrence of Intrauterine Adhesions Completed NCT02726971 Phase 1, Phase 2 Femoston
10 Open Randomized Trial of Clinical Efficiency and Safety of Cell Product of Autologous Bone Marrow-derived Mesenchymal Stem Cells for Reparative Treatment of Destructively Changed Endometrium in Patients With Repeated IVF Failures Completed NCT03166189 Phase 2
11 Fertility Restoration Using Autologous Adipose Tissue Derived Mesenchymal Stem Cells Completed NCT04432467 Phase 1, Phase 2
12 Umbilical Cord Plasma for Treating Endometrial Pathologies (Thin Endometrium / Asherman's Syndrome/ Endometria Atrophy). Recruiting NCT05095597 Phase 2 Oestraclin
13 Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair: a Prospective Randomised Pilot Study Terminated NCT02825849 Phase 2
14 Safety and Therapeutic Effect of Human Amniotic Epithelial Cells in Severe Refractory Asherman's Syndrome Unknown status NCT03223454 Phase 1
15 Clinical Safety Study of Human Embryonic Stem Cell Derived Mesenchymal Cells in the Treatment of Moderate and Severe Intrauterine Adhesions Unknown status NCT04232592 Phase 1
16 Cesarean Myomectomy : Safety and Risk of Intrauterine Synechiae Completed NCT03095014 Phase 1
17 Biomedical Study of Toxicity, Biodistribution, Expression and Cellular Characterization of Autologous CD133+ Stem Cells From Donors of Hematopoietic Progenitors (IGX1) in Murine Model With Asherman-induced Syndrome. Unknown status NCT03665649
18 Efficiency of INTERCOAT (Oxiplex/AP Gel) in Preventing Intrauterine Adhesion Formation in Hysteroscopic Surgery - a Prospective Double Blind Randomized Study Unknown status NCT01637974 INTERCOAT administration
19 Treatment of Intrauterine Adhesions and Its Distribution of Genital Tract Flora Unknown status NCT03731689 Intrauterine lavage therapy;Intrauterine gel-injection therapy
20 Amnion Graft for Preventing Intrauterine Adhesions Following Hysteroscopic Surgery Unknown status NCT02132104 Femoston
21 Prevention of Intrauterine Adhesions After Hysteroscopic Metroplasty With Autocross-linked Hyaluronic Acid Gel Unknown status NCT02404454
22 The Efficacy and Safety of the Dried Biological Amnion Graft Following Hysteroscopic Lysis for the Prevention of Postoperative Adhesions in Patients With Intrauterine Adhesions Unknown status NCT02496052 estradiol valerate tablets+dydrogesterone Tablets
23 Hysteroscopy Assisted Suction Curettage for Early Pregnancy Loss: Does it Reduce Retained Products of Conception and Postoperative Intrauterine Adhesions? Unknown status NCT04637373
24 Platelet-rich Plasma(PRP) Prevents Recurrence of Intrauterine Adhesions Unknown status NCT03629132
25 Use Of Hyaluronic Acid Gel To Prevent Intrauterine Adhesions In Hysteroscopic Surgery Unknown status NCT01464528 Early Phase 1 Hyaluronan
26 A Multi-center, Randomized, Single-blind, Controlled Clinical Trial of Treatment of Severe Asherman Syndrome by Collagen Scaffold Loaded With Autologous Bone Marrow Mononuclear Cells Completed NCT02680366
27 Impact of Mindfulness Based Stress Reduction on Anxiety, Depression and Quality of Life in Women With Intrauterine Adhesion:a Randomized Controlled Trial. Completed NCT02746679
28 Effects of Intrauterine Platelet Rich Plasma (PRP) on Endometrium and Pregnancy Rates in Patients With Suboptimal Endometrium Undergoing Frozen Embryo Transfer Completed NCT04424160
29 A Randomized Clinical Trial to Assess the Efficacy of Intrauterine Balloon Compared to Intrauterine Contraceptive Device Plus Foley Catheter in the Therapy for Uterine Adhesion After Hysteroscopic Adhesiolysis Completed NCT02867202
30 Intercoat (Oxiplex/AP Gel) for Preventing Intrauterine Adhesions Following Operative Hysteroscopy for Suspected Retained Products of Conception - a Prospective Randomized Pilot Study Completed NCT01377779 Oxiplex/AP gel;Normal Saline
31 Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Infertility Due to Severe Intrauterine Adhesions. Completed NCT02708277
32 Prevalence of Chronic Endometritis in Severe Intrauterine Adhesions and Role of Chronic Endometritis in Postoperative Recurrence of Severe Intrauterine Completed NCT02744807
33 Clinical Study of the Treatment of Infertility Caused by Recurrent Intrauterine Adhesions by Collagen Scaffold Loaded With Umbilical Cord -Derived Mesenchymal Stem Cells (UC-MSCs) Completed NCT02313415
34 Assessment of Uterine Access, Uterine Patency and Intrauterine Adhesions (IUA) 3, 6 and 12 Months Following Endometrial Ablation: A Prospective Single-Center Observational Study Completed NCT04824430
35 The Value of Using Platelet Rich Plasma After Hysteroscopic Lysis of Severe Intrauterine Adhesions (A Randomized Controlled Trial) Completed NCT03541746
36 Autocrosslinked Hyaluronic Acid Gel in Prevention of Intrauterine Adhesions After Bipolar Radiofrequency Endometrial Ablation: a Randomised, Controlled and Double Blind Study Completed NCT01829451
37 A Placebo Comparative, Evaluator Blinded, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of Medicurtain® in Patients With Hysteroscopy Completed NCT04638855
38 Endometrial Reconstruction by Human Regenerative Factors Derived From Platelet-Rich Plasma in Mice Models Recruiting NCT03249415
39 PREvention of Intrauterine Adhesion After Adhesiolysis With Novel Tri-block deGradable Polymer Film. Recruiting NCT04963179
40 The Cost-effectiveness of Anti-adhesion Treatment With HYALOBARRIER® GEL ENDO Versus no Gel Following the Removal by Hysteroscopy of Endometrial Polyps, Fibroids With Uterine Cavity Deformation, Uterine Septa, Intrauterine Adhesions or Retained Products of Conception for Improving Reproductive Outcome in Women Wishing to Become Pregnant: a Multi-centre, Parallel Group, Superiority, Double-blind, Randomized Controlled Trial Recruiting NCT03880435
41 Intrauterine Adhesions Prevention: the Use of Heparin Solution Compared to Application of Anti-adhesion Barrier Gel After Operative Hysteroscopy Recruiting NCT05257213 Heparin solution;Anti-adhesion barrier gel
42 The Value of Three-dimensional Ultrasound Applying in Pre and Postoperative Assessment and Prognosis of Intrauterine Adhesions Recruiting NCT04930913
43 Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions Recruiting NCT05003869
44 Reduction of Intrauterine Adhesions by Intrauterine Hyaluronic Acid Gel After Hysteroscopic Removal of Retained Products of Conception: Multicenter Prospective Randomized Trial Active, not recruiting NCT04975373 Intrauterine injection of hyaluronic acid
45 Establishment and Application of Endometrial 3D-organoid in Endometrial Injury Repair Not yet recruiting NCT05521932
46 Bone Marrow Derived Stem Cells Mobilization for Treatment of Asherman's Syndrome, Atrophic Endometrium, and Recurrent Implantation Failure Not yet recruiting NCT05343572 Early Phase 1 Plerixafor
47 Evaluation of Adhesions Formation Using Conventional Third Generation Endometrial Ablation With and Without Postoperative Application of an Intrauterine Adhesion Barrier Film Not yet recruiting NCT05414760
48 Prevalence of Intrauterine Adhesions After Abdominal Myomectomy Not yet recruiting NCT04030273
49 MONOBISY: Randomized Controlled Trial Comparing Intra Uterine Synechiae Occurence Using Bipolar Energy Compared With Monopolar Energy in Myoma Resection on Women Having Menorraghia and/or Infertility Withdrawn NCT02661087

Search NIH Clinical Center for Asherman's Syndrome

Genetic Tests for Asherman's Syndrome

Anatomical Context for Asherman's Syndrome

Organs/tissues related to Asherman's Syndrome:

MalaCards : Uterus, Cervix, Bone Marrow, Placenta, Bone, Endothelial

Publications for Asherman's Syndrome

Articles related to Asherman's Syndrome:

(show top 50) (show all 532)
# Title Authors PMID Year
1
Strategies for modelling endometrial diseases. 62
36050476 2022
2
Bioengineering trends in female reproduction: a systematic review. 62
35652272 2022
3
Successful live birth following hysteroscopic adhesiolysis under laparoscopic observation for Asherman's syndrome: A case report. 62
36405260 2022
4
Incidence and Clinical Implications of Placenta Accreta Spectrum After Treatment for Asherman Syndrome. 62
36442752 2022
5
Reproductive Outcomes and Overall Prognosis of Women with Asherman's Syndrome Undergoing IVF. 62
35970266 2022
6
Ultrasound and MRI appearance of abnormally adherent placenta in a woman with Asherman's syndrome. 62
35657771 2022
7
Endometrial regeneration in Asherman's syndrome and endometrial atrophy using Wharton's jelly-derived mesenchymal stem cells. 62
36196566 2022
8
First Use of a Novel Barrier Film in an Infertile Woman with Severe Asherman's Syndrome. 62
35705163 2022
9
Effect of intrauterine ozone therapy on Asherman syndrome, an experimental rat model. 62
36055047 2022
10
Mesenchymal stem cells to treat female infertility; future perspective and challenges: A review. 62
36340664 2022
11
Platelet-Rich Plasma: A Promising Regenerative Therapy in Gynecological Disorders. 62
36249659 2022
12
Endometrial preservation during resection of type II and type III submucosal fibroids. 62
36206803 2022
13
Human Endometrium-Derived Adventitial Cell Spheroid-Loaded Antimicrobial Microneedles for Uterine Regeneration. 62
35798313 2022
14
Uterine Factor Infertility, a Systematic Review. 62
36013146 2022
15
Successful Outcome in a Middle-Aged Woman With Secondary Infertility Using Donor Oocyte In Vitro Fertilization: A Case Report From a Rural Infertility Clinic. 62
36081974 2022
16
Transient and Prolonged Activation of Wnt Signaling Contribute Oppositely to the Pathogenesis of Asherman's Syndrome. 62
35955940 2022
17
Surgical uterus-preserving therapy after uterine rupture and haemorrhage due to placenta percreta in the first trimester following embolisation of the uterine arteries and B-Lynch suture in a previous pregnancy. 62
35798499 2022
18
Hysteroscopic findings after laparoscopic and open myomectomy with or without uterine cavity breach: historical cohort study. 62
34669526 2022
19
Short and long-term reproductive outcomes after hysteroscopic adhesiolysis for infertile women. 62
35616443 2022
20
Human Platelet-Rich Plasma Facilitates Angiogenesis to Restore Impaired Uterine Environments with Asherman's Syndrome for Embryo Implantation and Following Pregnancy in Mice. 62
35563855 2022
21
Resectoscopic Surgery Part III: Advanced Resectoscopic Surgery. 62
35158402 2022
22
Mesenchymal stem cell-based therapy and female infertility: limitations and advances. 62
35546752 2022
23
An Insight on the Role of Altered Function and Expression of Exosomes and MicroRNAs in Female Reproductive Diseases. 62
33825167 2022
24
A Patient-Centred Approach to Early Pregnancy Loss: The First 18 Months of a Canadian Outpatient Program for Early Pregnancy Loss (OPEL). 62
34973436 2022
25
Prenatal diagnosis of placenta accreta spectrum. 62
35230992 2022
26
Platelet Rich Plasma in Gynecology-Discovering Undiscovered-Review. 62
35564681 2022
27
Intrauterine administration of G-CSF for promoting endometrial growth after hysteroscopic adhesiolysis: a randomized controlled trial. 62
35147195 2022
28
Mesenchymal stem cells therapy: A promising method for the treatment of uterine scars and premature ovarian failure. 62
34798583 2022
29
Surgical treatment of Asherman syndrome and reproductive outcome. 62
35244019 2022
30
Cell-based therapy in thin endometrium and Asherman syndrome. 62
35090547 2022
31
"Adipose-derived mesenchymal stem cell therapy for the management of female sexual dysfunction: Literature reviews and study design of a clinical trial". 62
36247008 2022
32
Analysis of risk factors for obstetric outcomes after hysteroscopic adhesiolysis for Asherman syndrome: A retrospective cohort study. 62
33483955 2022
33
Intrauterine infusion of platelet-rich plasma for severe Asherman syndrome: a cutting-edge approach. 62
32514742 2021
34
Bio-modulated mice epithelial endometrial organoids by low-level laser therapy serves as an invitro model for endometrial regeneration. 62
34662815 2021
35
Making More Womb: Clinical Perspectives Supporting the Development and Utilization of Mesenchymal Stem Cell Therapy for Endometrial Regeneration and Infertility. 62
34945836 2021
36
Corrigendum to 'Endometrial membrane organoids from human embryonic stem cell combined with the 3D Matrigel for endometrium regeneration in asherman syndrome' [Bioactive Mater. 6 (2021) 3935-3946]. 62
34095618 2021
37
Endometrial membrane organoids from human embryonic stem cell combined with the 3D Matrigel for endometrium regeneration in asherman syndrome. 62
33937593 2021
38
Bioengineered endometrial hydrogels with growth factors promote tissue regeneration and restore fertility in murine models. 62
34428563 2021
39
Autologous platelet-rich plasma treatment for moderate-severe Asherman syndrome: the first experience. 62
34613578 2021
40
The implementation of routine procedural transvaginal sonography to decrease retained products of conception: a quality improvement initiative. 62
34602062 2021
41
Hysteroscopy as a Primary Tool in Exploration and Treatment of Infertility: Single Center Experience in Western Romania. 62
34679615 2021
42
Uterine synechiae after intrauterine device use: a case series. 62
33830411 2021
43
Recent Advances in Diagnosis and Management of Female Genital Tuberculosis. 62
34483510 2021
44
Avoiding Asherman's syndrome: refining our approach to uterine evacuation. 62
34330428 2021
45
Live births after Asherman syndrome treatment. 62
34130799 2021
46
Classification systems of Asherman's syndrome. An old problem with new directions. 62
33660561 2021
47
Successful Application of Combined Autologous Bone Marrow-Derived Stem Cells and Platelet-Rich Plasma in a Case of Severe Asherman Syndrome and Subsequent in vitro Fertilization Conception. 62
35197694 2021
48
Birth of a healthy infant after bone marrow-derived cell therapy. 62
34488290 2021
49
Fertility and pregnancy complications following chorioamnionitis. 62
34587848 2021
50
Uterine adhesion: Is luteal phase prior to follicular phase in uterine adhesiolysis? 62
34664846 2021

Variations for Asherman's Syndrome

Expression for Asherman's Syndrome

Search GEO for disease gene expression data for Asherman's Syndrome.

Pathways for Asherman's Syndrome

GO Terms for Asherman's Syndrome

Sources for Asherman's Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....